Overview
URGN market data
Price History
URGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.52 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.86 – $43.93 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.9K · P/B 25.38 · P/S 13.24.
Company News
UroGen Pharma shares are trading higher after Guggenheim maintained its Buy rating on the stock and raised its price target from $32 to $42.Benzinga · Jul 21, 2026, 2:46 PM
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42Benzinga · Jul 21, 2026, 1:57 PM
Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50Benzinga · Jul 16, 2026, 2:57 PM
UroGen Receives USPTO Notice Of Allowance For Patent Covering Treatment Of Recurrent LG-IR-NMIBC With Thermally Gelling Mitomycin; Claims Supported By ENVISION And ATLAS Trials, Patent To Expire July 2044Benzinga · Jul 15, 2026, 12:02 PM
UroGen Pharma Receives FDA IND Application Clearance For Its Investigational Oncolytic Virus UGN-501Benzinga · Jul 8, 2026, 12:05 PM
8-K filing — UroGen Pharma Ltd. (URGN)SEC EDGAR · Jun 23, 2026, 8:14 PM
UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTOBenzinga · Jun 2, 2026, 12:02 PM
UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder CancerBenzinga · May 15, 2026, 12:10 PM
UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution.Benzinga · May 13, 2026, 12:09 PM
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45Benzinga · May 11, 2026, 11:10 AM